Target Advantages Drawbacks Preliminary data
Neisseria Adhesin A- NadA Predicted molecular structure strikingly similar to the known virulence-associated. Based only in one antigen. Is capable of generating local and systemic cellular and humoral immunity when coadministered with mucosal adjuvants [26,52,53].
Surface Porin - PorA N. meningitidis strains express usually only one kind of porin class. Vaccines based on this porin are effective only against clonal epidemics Effective only against clonal epidemics [25,54].
Outer membrane vesicule - OMV MenBvac vaccine consists of several recently discovered, relatively conserved surface antigens, NadA, fHBP, and NHBA, and a PorA Protected only against homologous meningococal strains. All four doses of MenBvac are safe, no serious adverse events occurred [58,59].
rMenB-OMV -recombinant MenB with OMV vaccine consists of several recently discovered, relatively conserved surface antigens, NadA, fHBP, and NHBA, and a PorA Protected only against homologous meningococal strains. Clinical trials revealed that vaccinated individuals produce bactericidal antibodies, which protect against infection with homologous meningococcal strains [55,56].
Intranasal Neisseria OMVB Intranasal vaccination with OMV, presenting complex antigens mixture. Still in trials. Immunogenicity and safety of a group B vaccine proved. [60].
Table 4: Novel membrane proteins target in Neisseria meningitides.